Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies
oleh: Roger H. Kobayashi, Sudhir Gupta, Isaac Melamed, J. Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, Thomas Prescott Atkinson, Syed Rehman, Eva Turpel-Kantor, Jiří Litzman
| Format: | Article |
|---|---|
| Diterbitkan: | Frontiers Media S.A. 2022-12-01 |
Deskripsi
Subjek
primary immunodeficiencies; immunoglobulins; antibodies; SCIG; infections; infusion site reactions